Announcing availability: Beta nicotinamide mononucleotide

OYC Americas is pleased to announce availability of highly-qualified, fully physiologically-active β-nicotinamide mononucleotide (NMN) for laboratory research applications in academia and pharmaceuticals.

Recent studies have publicized this coenzyme as a potential key anti-aging factor, with initial results in mice showing exciting implications for age-related diseases such as diabetes, neurodegenerative disorders, and cardiac disease.

These studies demonstrated improvement in diet-induced glucose intolerance, restoration of age-related mitochondrial dysfunction, reduction of infarct area in response to ischemia/reperfusion, and a rescue effect for age-related decline in neural stem cells.

Given the revenue-generation potential for effective anti-aging medications, and given the upswing in diabetes throughout the population, the NMN coenzyme is in high demand for research studies in laboratories across the United States.

This entry was posted in News. Bookmark the permalink.